Vpriv® (velaglucerase alfa)

Vpriv (velaglucerase alfa) is covered only for the FDA‑approved indication of Type 1 Gaucher disease and is not supported for other Gaucher types or off‑label uses. Approval is for up to one year with dosing 60 U/kg IV every other week and requires documented diagnostic confirmation (reduced β‑glucocerebrosidase activity in leukocytes/fibroblasts or molecular genetic testing showing a GBA mutation), prescription by or consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist, and documentation to justify renewal.

"Vpriv is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.